Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

New Microplate Reader Optimized for Fluorescent and Bioluminescent Assays

By BiotechDaily International staff writers
Posted on 13 Feb 2014
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Biotech and other life science researchers now have available a new microplate reader system that provides superior sensitivity, performance, and flexibility with minimal user intervention.

Promega Corporation (Madison, WI, USA) has launched the GloMax Discover, an integrated multimode detection plate-reader system. This system was designed to enable investigators to easily study cell signaling and metabolism, while monitoring cell viability, apoptosis, and cytotoxicity, or to study gene expression with a wide variety of reporter assays.

The instrument offers a broad dynamic range for both strong and weak bioluminescence experimental samples, superior luminescence sensitivity, and low well-to-well cross talk, which enables users to generate more usable data from each experiment. The GloMax Discover provides flexible use of filters for fluorescence intensity, BRET (bioluminescence resonance energy transfer), FRET (fluorescence resonance energy transfer), filtered luminescence, and UV-visible absorbance measurements. In addition, the system encourages seamless integration with industry-leading bioluminescent assays.

The GloMax Discover is driven by proprietary software that provides quick and easy navigation through the control options, preloaded assay protocols, and drag-and-drop protocol customization.

Michael Bjerke, global product manager, detection at Promega, said, “Scientific discoveries not only require the right type of assay to achieve the necessary sensitivity, dynamic range, and reproducibility, they require the right type of instrument. Instruments with enhanced optical capability, such as our GloMax systems with high quality luminescence, enable superior assay performance and experimental design.”

Related Links:

Promega Corporation



Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.